Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07243782
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

Study Details

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea

Key Dates

Start date
Dec 22, 2025
Status verified
Mar 2026
Primary completion
Jun 15, 2027
Completion
Jun 15, 2027

Study Design

Enrollment
76 participants (estimated)

Arms

  • Arm: Secukinumab - HS
    Participants with Hidradenitis Supurativa who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.
  • Arm: Secukinumab - Pediatric plaque psoriasis
    Participants with pediatric plaque psoriasis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.
  • Arm: Secukinumab - JIA
    Participants with juvenile idiopathic arthritis who are receiving or will receive Cosentyx after the start of this study in routine clinical practice.

Primary Outcome Measure

Number of participants having Adverse Events (AEs) and Serious Adverse Events (SAEs) within each indication [ Time Frame: Up to 24 weeks ]

Central Contacts

Related Studies